Hypothesis

The epigenetic age of the gut microbiome, measured by microbiome‑specific DNA methylation clocks, predicts systemic inflammaging and accelerates brain aging independently of host chronological age. A dysbiotic, epigenetically older microbiome increases release of pro‑inflammatory microbial extracellular vesicles (mEVs) that carry age‑associated miRNAs and LPS, which cross a compromised gut barrier, activate hepatic acute‑phase responses, and sensitize microglia via vagal and humoral pathways, thereby driving neuroinflammation and cognitive decline.

Mechanistic Reasoning

1. Microbiome epigenetic aging – Recent multi‑omics shows age‑related loss of SCFA producers and gain of pathobionts, but the microbiome itself harbors an epigenetic program that shifts with host age 1. We propose that microbial DNA methylation age (mDNAmAge) diverges from host age in individuals with rapid inflammaging.
2. mEV cargo – Aging‑associated microbiota produce mEVs enriched in miR‑155, miR‑146a and LPS 2. These vesicles translocate through a leaky epithelium, delivering inflammatory signals to the liver and brain.
3. Host response – Hepatic uptake of mEVs triggers IL‑6 and CRP production, amplifying systemic inflammaging 3. Simultaneously, vagal afferents detect mEV‑derived LPS, priming microglia to a hyperreactive state, which exacerbates amyloid‑β deposition and tau pathology 4.
4. Bidirectional feedback – Host corticotropin‑releasing factor alters gut motility, further selecting for epigenetically aged microbes, closing the loop.

Testable Predictions

• Individuals with higher mDNAmAge than chronological age will show elevated serum LPS‑binding protein, IL‑6, and fecal calprotectin, and will exhibit faster hippocampal atrophy on MRI over 12 months, independent of host age or APOE status.
• Oral administration of a defined consortium of youthful, SCFA‑producing strains (e.g., Faecalibacterium prausnitzii, Roseburia hominis) will reduce mDNAmAge, lower mEV‑associated miR‑155 levels, and improve memory scores in a randomized controlled trial.
• Pharmacological blockade of TLR4 will attenuate the effect of high mDNAmAge on neuroinflammation, indicating that LPS carried by mEVs is a necessary mediator.

Falsifiability

If longitudinal measurements reveal no correlation between mDNAmAge and inflammatory biomarkers or cognitive trajectories, or if restoring youthful microbiota fails to modify mDNAmAge or inflammaging markers, the hypothesis would be refuted.

Implications

This framework shifts focus from host‑centric inflammaging to a measurable microbial aging metric, enabling personalized interventions that target the microbiome’s epigenetic state to slow brain aging.